New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

Lung Cancer Canada (LCC) and Boehringer Ingelheim Canada (Boehringer) are pleased to announce a new collaboration aimed at reimagining detection and accelerating innovation in non-small cell lung ...

Lung cancer is no longer solely a smoker's disease, with air pollution emerging as a significant risk factor affecting ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform ...

Lung Cancer Canada, Boehringer Ingelheim Canada collaborate to advance innovation in non-small cell lung cancer diagnostics: Toronto Saturday, November 29, 2025, 17:00 Hrs [IST] L ...

Despite recommendations for posttreatment surveillance in lung cancer patients, there is wide variability in the follow-up ...

When treated early, Stage 1 lung cancer patients have a five-year survival rate of above 70 per cent. Read more at straitstimes.com. Read more at straitstimes.com.

Kentucky has historically led the nation in lung cancer rates, but the statistics are turning around thanks to a decade-long statewide effort to ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...

The Oncomine Dx Target Test received its first approval by the FDA as a next-generation sequencing (NGS) CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 ...